Satsuma Pharmaceuticals, Inc.
STSA · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $44,092 | $37,635 | $36,270 | $24,196 |
| G&A Expenses | $15,126 | $13,531 | $12,058 | $4,685 |
| SG&A Expenses | $15,126 | $13,531 | $12,058 | $4,685 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$1 |
| Operating Expenses | $59,218 | $51,166 | $48,328 | $28,881 |
| Operating Income | -$70,947 | -$51,166 | -$48,328 | -$28,881 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $892 | -$6 | $765 | $706 |
| Pre-Tax Income | -$70,055 | -$51,172 | -$47,563 | -$28,175 |
| Tax Expense | -$892 | $92 | $111 | $340 |
| Net Income | -$69,163 | -$51,264 | -$47,674 | -$28,515 |
| % Margin | – | – | – | – |
| EPS | -2.16 | -1.76 | -2.74 | -4.86 |
| % Growth | -22.7% | 35.8% | 43.6% | – |
| EPS Diluted | -2.16 | -1.76 | -2.74 | -4.86 |
| Weighted Avg Shares Out | 32,025 | 29,174 | 17,406 | 5,864 |
| Weighted Avg Shares Out Dil | 32,025 | 29,174 | 17,406 | 5,864 |
| Supplemental Information | – | – | – | – |
| Interest Income | $905 | $157 | $1,115 | $1,189 |
| Interest Expense | $13 | $163 | $350 | $482 |
| Depreciation & Amortization | $12,634 | $550 | $1,115 | $1,188 |
| EBITDA | -$58,313 | -$50,616 | -$46,098 | -$26,505 |
| % Margin | – | – | – | – |